Evolus, Inc.
EOLSNASDAQHealthcareDrug Manufacturers - Specialty & Generic
As of Oct 16, 2026 close
- Market cap
- $499.08M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $3.86$9.31
- Volume (live)
- -
- Avg. volume (3M)
- 798.34K
Evolus (EOLS) Stock Price & Financial Analysis
Evolus Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $7.02 - $7.61 |
|---|---|
| 52-Week High | $9.31 |
| 52-Week Low | $3.86 |
| Open | $7.61 |
| Volume (last close) | 761.68K |
| Average Volume (3M) | 798.34K |
| Revenue (TTM) | 316.49M |
|---|---|
| Net Income (TTM) | -34.33M |
| Free Cash Flow (TTM) | -20.17M |
| EPS (TTM) | −$0.53 |
| Profit Margin | -10.85% |
| Operating Margin | -6.51% |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 499.08M |
|---|---|
| Shares Outstanding | 65.93M |
| Price to Sales (P/S) | 1.58 |
| Price to Book (P/B) | -16.15 |
| EV/EBITDA | -71.00 |
| 50-Day MA | $8.10 |
|---|---|
| 200-Day MA | $6.18 |
| 1-Year Change | +18.28% |
Source: Market prices and company fundamentals. Data as of Oct 16, 2026. Data sources and methodology
Evolus at a Glance
As of the Oct 16, 2026 close, Evolus (EOLS) has a market capitalization of $499.08M. The stock trades at 1.6× sales. Over the trailing twelve months it lost $34.33M on revenue of $316.49M and burned $20.17M of free cash flow. Revenue grew 13.9% year over year.
As of its latest reported balance sheet, it holds $45.17M in cash and securities against $159.32M of debt, a net debt position of $114.15M.
Evolus does not currently pay a dividend.
The share price is up 18.3% over the past year. At $7.10 (the Oct 16, 2026 close) it sits within its 52-week range of $3.86 to $9.31, above its 200-day moving average of $6.18.
Based on 6 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $14.33, 101.8% above the Oct 16, 2026 close.
Frequently Asked Questions About Evolus
What is the current stock price for EOLS?
As of the Oct 16, 2026 close, EOLS stock trades at $7.10. The 52-week range is $3.86–$9.31, with a day range of $7.02–$7.61.
What is the P/E ratio for EOLS?
The P/E ratio (Price-to-Earnings) for EOLS is shown in the Key Statistics section. This valuation metric helps compare Evolus, Inc. to industry peers.
Does EOLS pay dividends?
Evolus does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for EOLS?
Based on ratings from 6 professional analysts over the last 90 days, the consensus for EOLS is Buy. The average 12-month price target is $14.33, a 101.8% upside from the Oct 16, 2026 close of $7.10.
What is the market cap of EOLS?
As of the Oct 16, 2026 close, Evolus's market capitalization is $468.1M, classifying it as a small-cap company. Evolus operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry.